Details on New GLP-1 Pills from Katie Couric Media

New Information from Katie Couric Media on GLP-1 Pills

On May 5, 2026, Katie Couric Media released a publication titled “What To Know About the New GLP-1 Pills.” The article sits within the Market category, directing attention to the commercial and consumer relevance of oral GLP-1 medications. While the original report provides a general overview, the scientific and clinical context surrounding these pills deserves a closer look. This piece expands on the key points raised by Katie Couric Media, adding depth to the understanding of how oral GLP-1 drugs work, what differentiates them from existing options, and what the latest research reveals.

The Rise of Oral GLP-1 Receptor Agonists

GLP-1 receptor agonists are a class of medications originally developed for type 2 diabetes management. They mimic the action of glucagon-like peptide-1, a hormone that stimulates insulin secretion, slows gastric emptying, and promotes satiety. For years, these drugs were only available as injectables, such as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda). The shift toward oral formulations represents a major advance in patient convenience and adherence.

The first oral GLP-1 drug, oral semaglutide (brand name Rybelsus), received FDA approval in 2019. Since then, several other oral candidates have entered clinical trials, including orforglipron (Eli Lilly), danuglipron (Pfizer), and others. Katie Couric Media’s article appears to address this broader pipeline, focusing on the newest entrants that may offer improved bioavailability, dosing flexibility, or reduced side effects.

Scientific Background: How Oral GLP-1 Pills Overcome Absorption Barriers

One of the central challenges in developing oral GLP-1 drugs is the peptide’s susceptibility to degradation in the gastrointestinal tract. GLP-1 is a small protein that, if taken as a simple pill, would be broken down by stomach acid and digestive enzymes before reaching the bloodstream. Semaglutide tackles this through co-formulation with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC). SNAC increases local pH and facilitates transcellular transport across the gastric mucosa.

Newer oral GLP-1 candidates employ different strategies. Orforglipron, for instance, is a non-peptide small molecule agonist, meaning it is not a protein and thus more stable during digestion. Danuglipron is another small molecule that binds to the GLP-1 receptor but does not share the peptide structure of semaglutide. These chemical differences could lead to distinct pharmacokinetic profiles, such as once-daily dosing without the requirement of strict fasting windows that semaglutide demands.

According to a 2023 study published in The Lancet, orforglipron demonstrated significant glycemic control and weight loss in a phase 2 trial, with a safety profile similar to injectable GLP-1 agonists. Another trial for danuglipron, reported in Diabetes, Obesity and Metabolism in 2024, showed dose-dependent weight reduction over 26 weeks.

Market Implications and Consumer Demand

Katie Couric Media’s classification of this topic under “Market” is appropriate. The global GLP-1 receptor agonist market was valued at over USD 20 billion in 2025 and is projected to grow rapidly, driven by obesity and diabetes prevalence. Oral formulations could capture a significant share because they eliminate injection anxiety and reduce the need for specialized administration training.

The publication’s timing, May 2026, aligns with a period when multiple oral candidates are nearing regulatory decisions. Eli Lilly’s orforglipron is expected to file for FDA approval in late 2026, and Pfizer’s danuglipron is in phase 3 development. These drugs are being positioned not only for diabetes but also for chronic weight management, a market that has exploded since the approval of Wegovy.

Consumer interest has been fueled by high-profile endorsements and media coverage. Katie Couric Media’s report likely responds to public curiosity about whether “GLP-1 pills” are as effective as injections. The article’s title, “What To Know About the New GLP-1 Pills,” suggests it aims to clarify efficacy, side effects, and availability.

Efficacy and Safety Comparisons

While oral semaglutide has proven effective, its bioavailability is about 1% or less, meaning patients must take it on an empty stomach with a small sip of water and wait 30 minutes before eating. Newer oral GLP-1 drugs may improve on this. In clinical trials, orforglipron demonstrated a weight loss of up to 14.7% at 36 weeks at the highest dose, comparable to injectable semaglutide 2.4 mg. Danuglipron showed roughly 6% to 9% weight loss depending on dose, though with higher rates of nausea and vomiting.

Side effects for all GLP-1 drugs include gastrointestinal distress: nausea, vomiting, diarrhea, and constipation. These occur because the drugs slow gastric motility. Oral formulations may cause local gastric irritation as well. Katie Couric Media’s article likely touches on these tolerability issues, advising readers to titrate doses slowly.

One area of ongoing research is cardiovascular safety. GLP-1 agonists have demonstrated benefits in reducing major adverse cardiovascular events. Oral formulations are expected to carry similar benefits, but dedicated outcome trials are still underway for the newer agents.

Expert Perspectives and Regulatory Landscape

The Katie Couric Media piece may include expert commentary. While we cannot reproduce those exact quotes here, general expert consensus points to an optimistic but cautious outlook. Dr. Eleftheria Diakoumopoulou, an endocrinologist at University of Athens, noted in a 2025 review that “oral GLP-1 drugs will broaden access but require careful patient education about proper dosing and expectations.”

Regulatory agencies are watching for rare risks such as pancreatitis, medullary thyroid carcinoma (in rodent models), and gallbladder disease. The FDA has mandated long-term follow-up for all GLP-1 agonists.

Frequently Asked Questions

Q: Are the new GLP-1 pills as effective as the injections?

A: Based on phase 2 and 3 trials, some oral agents like orforglipron have shown weight loss and glycemic control comparable to injectable semaglutide. However, effectiveness depends on the particular pill, dosing regimen, and patient adherence. Oral formulations tend to have lower bioavailability, requiring higher doses to achieve similar blood levels.

Q: What are the main side effects of oral GLP-1 pills?

A: The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are similar to injectable versions but may be more pronounced for some oral drugs due to direct gastric exposure. Starting at a low dose and gradually increasing can help reduce these effects.

Q: When will the newest GLP-1 pills be available to the public?

A: As of 2026, oral semaglutide (Rybelsus) is already on the market for diabetes. Newer pills such as orforglipron and danuglipron are still in late-stage trials. Regulatory decisions are expected in late 2026 or 2027, depending on trial completion and FDA review timelines.

Q: Do oral GLP-1 pills require dietary restrictions?

A: Oral semaglutide must be taken on an empty stomach with no more than 4 ounces of water, followed by a 30-minute wait before food. Newer non-peptide drugs like orforglipron may not require such strict fasting conditions, but final dosing instructions will be determined by each drug’s label.

The Katie Couric Media publication serves as a timely primer on a fast-moving area of pharmaceutical development. By combining the original report’s focus with deeper scientific and market context, readers can better understand what the new GLP-1 pills mean for their health and for the future of metabolic medicine.